Cargando…

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension

METHODS: In this retrospective observational study, we analyzed all patients with pulmonary arterial hypertension undergoing LenusPro® pump implantation between November 2013 and October 2019 at our center. Periprocedural safety was assessed by describing all complications that occurred within 28 da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamp, Jan C., Fuge, Jan, Karsten, Jan F., Rümke, Stefan, Hoeper, Marius M., Park, Da-Hee, Kühn, Christian, Olsson, Karen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126130/ https://www.ncbi.nlm.nih.gov/pubmed/33992098 http://dx.doi.org/10.1186/s12890-021-01541-3

Ejemplares similares

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Oral iron supplementation with ferric maltol in patients with pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2020)

Capillary pCO(2) helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction
por: Olsson, Karen M, et al.
Publicado: (2015)

Health Disparities and Differences in Health-Care-Utilization in Patients With Pulmonary Arterial Hypertension
por: Park, Da-Hee, et al.
Publicado: (2022)

Acute hemodynamic effects of adaptive servoventilation in patients with pre-capillary and post-capillary pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2015)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2020)

Metacognitive Therapy for Adjustment Disorder in a Patient With Newly Diagnosed Pulmonary Arterial Hypertension: A Case Report
por: Winter, Lotta, et al.
Publicado: (2020)

Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study
por: Fuge, Jan, et al.
Publicado: (2022)

Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension
por: Park, Da Hee, et al.
Publicado: (2021)

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2023)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
por: Kopp, Garance, et al.
Publicado: (2020)

Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension
por: Caldarone, Flora, et al.
Publicado: (2022)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension
por: Dering, Madelaine-Rachel, et al.
Publicado: (2022)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2023)

Childhood Trauma in Patients With PAH—Prevalence, Impact on QoL, and Mental Health—A Preliminary Report
por: Park, Da-Hee, et al.
Publicado: (2022)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension
por: Gall, Henning, et al.
Publicado: (2021)

Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension
por: Lepsy, Nicole, et al.
Publicado: (2022)

Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension
por: Olsson, Karen M., et al.
Publicado: (2021)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
por: Kramm, Thorsten, et al.
Publicado: (2018)

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension
por: Gleason, James Benjamin, et al.
Publicado: (2015)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
por: Feldman, Jeremy P., et al.
Publicado: (2021)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
por: De Bie, Felix Rafael, et al.
Publicado: (2022)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
por: Kumar, Parag, et al.
Publicado: (2016)

Implantable system for treprostinil: a real-world patient experience study
por: Shapiro, Shelley, et al.
Publicado: (2020)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Periprocedural considerations of transcatheter aortic valve implantation for anesthesiologists
por: Afshar, Ata Hassani, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ulmivtt1u0mibcvtqdofalirar